Mandel Dana E, Malemud Charles J, Askari Ali D
Department of Medicine, Division of Rheumatic Diseases, Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center, Cleveland, OH 44106-5076, USA.
Int J Mol Sci. 2017 May 18;18(5):1084. doi: 10.3390/ijms18051084.
Idiopathic inflammatory myopathies (IIMs) are a group of autoimmune muscle diseases with significant morbidity and mortality. This review details and updates the pathogenesis and emerging importance of myositis-specific antibodies in the development of IIMs. An increase in the understanding of how these myositis-specific antibodies play a role in IIMs has led to the further categorization of IIMs from the traditional polymyositis versus dermatomyositis, to additional subcategories of IIMs such as necrotizing autoimmune myositis (NAM). The diagnosis of IIMs, including manual muscle testing, laboratory studies, and non-invasive imaging have become important in classifying IIM subtypes and for identifying disease severity. Treatment has evolved from an era where glucocorticoid therapy was the only option to a time now that includes traditional steroid-sparing agents along with immunoglobulin therapy and biologics, such as rituximab.
特发性炎性肌病(IIMs)是一组具有显著发病率和死亡率的自身免疫性肌肉疾病。本综述详细阐述并更新了肌炎特异性抗体在IIMs发病机制中的作用及新的重要性。对这些肌炎特异性抗体如何在IIMs中发挥作用的认识不断增加,导致IIMs从传统的多发性肌炎与皮肌炎进一步分类为其他IIMs亚类,如坏死性自身免疫性肌病(NAM)。IIMs的诊断,包括徒手肌力测试、实验室检查和非侵入性成像,对于IIMs亚型分类和疾病严重程度识别变得至关重要。治疗已从糖皮质激素治疗是唯一选择的时代发展到现在包括传统的类固醇节省剂、免疫球蛋白治疗以及生物制剂(如利妥昔单抗)的时代。